It’s been a demanding year for the pharma industry. There’s a more aggressive FTC, a changing FDA, tough market conditions, and a legal fight over the drug pricing provisions in the Inflation Reduction Act.
Welcome to pharma’s “age of uncertainty,” according to Evaluate’s latest report, which…
Click here to view original post
